Aarti Drugs Ltd - 524348 - Corporate Action-Updates on Buy back
Extinguishment of Equity Shares in connection with the Buy back and Reconciliation of share capital of the Company04-06-2019
04-06-2019
AARTI DRUGS LTD. - 524348 - Reg.24(A)-Annual Secretarial Compliance
Annual Secretarial Compliance Report Sr. No. Particulars Details 1Period for which the report has been issued 31/03/2019 2Date of Report15/05/2019 3 Name of the Certifying Firm Sunil M. Dedhia & Co. 4 Name of the Certifying Individual CS Sunil M. Dedhia 5Membership TypeFCS 6 Membership Number 3483 7 CP No. 2031 8 Whether any observations/qualification reported by the Secretarial Auditor ? NO30-05-2019
AARTI DRUGS LTD. - 524348 - Announcement under Regulation 30 (LODR)-Investor Presentation
Please find enclosed presentation of the Company for your records.29-05-2019
Aarti Drugs Ltd - 524348 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Please find enclosed herewith copy of the press release issued by the Company on May 16, 2019.16-05-2019
AARTI DRUGS LTD. - 524348 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
This is to inform you that Quarterly Conference Call for Investors and Analysts has been scheduled on Thursday, May 16, 2019 at 4:30 PM IST to discuss the Company's Q4 FY19 Results. Please find attached herewith invitation for the same.15-05-2019
AARTI DRUGS LTD. - 524348 - Announcement under Regulation 30 (LODR)-Dividend Updates
We wish to inform you that the Board of Directors at its meeting held on Wednesday, May 15, 2019 has recommended a Dividend @ 10% i.e. Rs. 1/-(Rupee one) per Equity Share of face value of Rs.10/- for the financial year 2018-2019.15-05-2019
AARTI DRUGS LTD. - 524348 - Outcome Of Board Meeting Held Today I.E. Wednesday, May 15, 2019 Pursuant To Regulation 33 And Regulation 30 Read With Para A Of Part A Of Schedule III Of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015.
Pursuant to Regulation 33 and Regulation 30 read with Para A of Part A of Schedule III of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, we inform you that the Board of Directors at its Meeting held today i.e. Wednesday, May 15, 2019 had inter-alia considered and approved the following:- a)Statement of Audited Financial Results (Standalone & Consolidated) for the Quarter & year ended March 31, 2019 (attached); b)The Audit Report(s) by M/s. Kirtane & Pandit LLP, Chartered Accountants, the Statutory Auditors of the Company on the Standalone and Consolidated Financial Results for the quarter and year ended March 31, 2019 along with the declaration in respect of Audit Report(s) with unmodified opinion for the Financial Year ended on March 31, 2019 (attached); c)Recommended the Final Dividend @ Rs. 1/-(Rupee One) i.e. (10%) per share of Rs. 10/- each for the Financial year ended 2018-2019.15-05-2019
Aarti Drugs Ltd - 524348 - Board to consider Final Dividend
Aarti Drugs Ltd has informed BSE that a meeting of the Board of Directors of the Company will be held on May 15, 2019, inter alia, to transact the following;1. Consider, approve and take on record Audited Financial Results for the quarter and year ended March 31, 2019.2. Consider and recommend final dividend, if any, for the year ended March 31, 2019. .08-05-2019
Aarti Drugs Ltd - 524348 - Board Meeting Intimation for Regulation 29 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
AARTI DRUGS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 15/05/2019 ,inter alia, to consider and approve This is to inform you that the next meeting of the Board of Directors of the Company is scheduled to be held on Wednesday, May 15, 2019 inter-alia to; 1) Consider, approve and take on record Audited Financial Results for the quarter and year ended March 31, 2019. 2) Consider and recommend final dividend, if any, for the year ended March 31, 2019.07-05-2019